Who likes selling Bydureon? Honest answers please!

Quote
anonymous said:
Teams pissed to be getting the needle back. No one wants the portfolio again after leadership bungled it and split us off on the first place. Now we get to clean up their mess. No thanks.
Click to expand...


Ha!! This is too funny. Cleaning up the injectable mess. The only reason they are going to 70/30 is because a me to product like Farxiga isn't being sold by the oral reps. Share is dipping and the competitors have no significant advantage. The SGLT2 market is a pure relationship sell. We are even giving it away and Invokana isn't. GLP1's actually have real competition.
 




anonymous said:
Ha!! This is too funny. Cleaning up the injectable mess. The only reason they are going to 70/30 is because a me to product like Farxiga isn't being sold by the oral reps. Share is dipping and the competitors have no significant advantage. The SGLT2 market is a pure relationship sell. We are even giving it away and Invokana isn't. GLP1's actually have real competition.
Click to expand...
Calm down harpoon boy , you need us , we have the relationship to lift your sorry ass -whale hunters with that harpoon of a needle out of the sorry mesh you are in ! Lol
 




















Top Bottom
Back
Quote